SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "L773:0732 183X OR L773:1527 7755 ;conttype:(scientificother)"

Sökning: L773:0732 183X OR L773:1527 7755 > Övrigt vetenskapligt/konstnärligt

  • Resultat 1-10 av 455
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  •  
2.
  •  
3.
  •  
4.
  •  
5.
  •  
6.
  • Bergerot, Cristiane Decat, et al. (författare)
  • Frustration and distress during treatment for advanced renal cell carcinoma
  • 2018
  • Ingår i: Journal of Clinical Oncology. - Univ Fed Sao Paulo UNIFESP, Sao Paulo, Brazil. KCCure, Alexandria, VA USA. City Hope Comprehens Canc Ctr, Monrovia, CA USA. Duke Univ, Durham, NC USA. Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. Umea Univ, Umea, Sweden. Netherlands Canc Inst, Amsterdam, Netherlands. City Hope Comprehens Canc Ctr, Duarte, CA USA. Ludwig Maximilians Univ Munchen, Univ Hosp Munich Grosshadern, Munich, Germany. City Hope Natl Med Ctr, Duarte, CA USA. : AMER SOC CLINICAL ONCOLOGY. - 0732-183X .- 1527-7755. ; 36:34
  • Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)
  •  
7.
  • Bergh, Jonas C. S., et al. (författare)
  • Docetaxel, trastuzumab, pertuzumab versus trastuzumab emtansine as neoadjuvant treatment of HER2-positive breast cancer : results from the Swedish PREDIX HER2 trial identifying a new potential de-escalation standard?
  • 2019
  • Ingår i: Journal of Clinical Oncology. - : American Society of Clinical Oncology. - 0732-183X .- 1527-7755. ; 37:15, s. 501-501
  • Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)abstract
    • Background: Neoadjuvant therapy produces high rates of pathological complete response (pCR) and is the standard of care in HER2 positive breast cancer; however, the optimal treatment regimen remains to be established. Methods: In this randomized phase II study patients ≥18 years with HER2 positive breast cancer > 20mm or verified lymph node metastases were randomized to 6 courses of docetaxel, trastuzumab and pertuzumab (DTP, group A) or trastuzumab emtansine (T-DM1, group B), q 21 days. The protocol allowed switch to the competing treatment upon lack of response or drug-related severe toxicity. Patients received postoperative epirubicin+cyclophosphamide, trastuzumab for a total of one year and endocrine therapy. Accrual was completed in October 2018 after randomization of 202 patients, data on pCR were available for 190 at the time for this abstract submission. Median age, 52 years (26-74), menopausal status, histological type and grade were well balanced between the treatment groups. 62.6% of the tumors were hormone receptor (HR) positive. Results: Primary endpoint was pathological objective response. 190 patients completed the protocol-specified preoperative treatment. pCR was achieved in 45.3% of patients, 46.4% in patients treated with DTP and 44.1% with T-DM1 (chi-sq., p = 0.75). In HR-positive tumors, pCR was obtained in 35.3% of patients, 35.9% in group A vs. 34.6% in group B (p = 0.87); in HR-negative tumors, the overall pCR rate was 62.0%, 66.7% in group A vs. 57.9% in group B (p = 0.45). Severe (grade 3/4) toxicity was reported at 68 occasions related to DTP, compared with 16 related to T-DM1, 26 vs. 3 caused by febrile neutropenia. Significantly better quality of life was reported by patients treated with T-DM1. Conclusions: Our data on TDM-1 demonstrates similar efficacy and less toxicity, in particular for patients with HER2 and HR positive cancers, being a potential new standard for neoadjuvant therapy. Clinical trial information: NCT02568839.
  •  
8.
  •  
9.
  •  
10.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 455
Typ av publikation
konferensbidrag (353)
tidskriftsartikel (101)
annan publikation (1)
Typ av innehåll
övrigt vetenskapligt/konstnärligt  (455)Ta bort avgränsningen
Författare/redaktör
Bergh, JCS (25)
Bergh, J (21)
Hansson, J. (17)
Glimelius, B (15)
Jonsson, B (14)
Nahi, H (13)
visa fler...
Johansson, H (11)
Glimelius, Bengt (11)
Mellstedt, H (11)
Avall-Lundqvist, E (11)
Tandstad, T (11)
Eklund, M (10)
Hellstrom, M (10)
Lind, PA (10)
Usmani, SZ (10)
Eriksson, H (9)
Masucci, GV (9)
Hatschek, T (8)
Hall, P (8)
Lambe, M (8)
Gronberg, H (8)
Greil, R (8)
Cohn-Cedermark, G (8)
Harmenberg, U. (8)
Yachnin, J (8)
Stahl, O (8)
Helgadottir, H (8)
Wahlin, BE (8)
Ullenhag, GJ (8)
Gnant, M. (7)
Sandstrom, P. (7)
Wilking, U (7)
Plesner, T (7)
Nilsson, S. (7)
Dahl, O. (7)
Matikas, A (7)
Pfeiffer, P (7)
Wilking, N (7)
Bergh, Jonas C. S. (7)
Osterborg, A (6)
Moreau, P (6)
Fornander, T (6)
Sorbye, H. (6)
Nordstrom, T (6)
Brandberg, Y (6)
Scolyer, RA (6)
Daugaard, G (6)
Chari, A (6)
Mercke, C (6)
Foukakis, Theodoros (6)
visa färre...
Lärosäte
Karolinska Institutet (394)
Uppsala universitet (31)
Umeå universitet (21)
Lunds universitet (10)
Örebro universitet (8)
Kungliga Tekniska Högskolan (6)
visa fler...
Göteborgs universitet (4)
Linköpings universitet (2)
Stockholms universitet (1)
Handelshögskolan i Stockholm (1)
Blekinge Tekniska Högskola (1)
visa färre...
Språk
Engelska (455)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (69)
Naturvetenskap (1)
Teknik (1)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy